Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Targeting head and neck cancer by IL-2-mediated gene therapy: From bench to bedside - A review.
Autore:
Lang, S; Zeidler, R; Pauli, C; Andratschke, M; Wollenberg, B;
Indirizzi:
Univ Munich, Klinikum Grosshadern, Klin & Poliklin Hals Nasen & Ohrenkranke, D-81377 Munich, Germany Univ Munich Munich Germany D-81377 Ohrenkranke, D-81377 Munich, Germany
Titolo Testata:
LARYNGO-RHINO-OTOLOGIE
fascicolo: 4, volume: 80, anno: 2001,
pagine: 191 - 195
SICI:
1615-0007(200104)80:4<191:THANCB>2.0.ZU;2-4
Fonte:
ISI
Lingua:
GEO
Soggetto:
SQUAMOUS-CELL CARCINOMA; TUMOR-INFILTRATING LYMPHOCYTES; DOSE RECOMBINANT INTERLEUKIN-2; ACTIVATED KILLER CELLS; IN-VITRO; ORAL-CANCER; NK CELLS; MODEL; IMMUNOTHERAPY; INJECTIONS;
Keywords:
squamous cell carcinoma of the head and neck gene therapy; interleukin 2; IL-2;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Lang, S Univ Munich, Klinikum Grosshadern, Klin & Poliklin Hals Nasen & Ohrenkranke, Marchioninistr 15, D-81377 Munich, Germany Univ Munich Marchioninistr 15 Munich Germany D-81377 ich, Germany
Citazione:
S. Lang et al., "Targeting head and neck cancer by IL-2-mediated gene therapy: From bench to bedside - A review.", LARY RH OTO, 80(4), 2001, pp. 191-195

Abstract

Targeting Head and Neck Cancer by IL-2-Mediated Gene Therapy: From Bench to Bedside - A Review. Suppressed cellular immunity is common in patients with squamous cell carcinoma of the head and neck (HNSCC). It was demonstrated in previous studies that administration of interleukin 2 (IL-2) results in enhanced antitumoral immunity in vitro as well as in vivo. Since the serum half-life of IL-2 is relatively short, repeated applications are necessary to achieve therapeutically effective serum concentrations, but this strategy might cause severe side effects. Therefore, methods that provide high local cytokine levels over a prolonged period of time without the need for repeated injections are desirable. Gene therapy as an innovative treatment approach using tumor cells stably transduced to produce IL-2 might meet these criteria. In vitro manipulated tumor cells, if readministered in the vicinity of non-manipulated tumor cells, may enhance a specific anti-tumor response in vivo without systemic side effects. The present manuscript reviews the current literature dealing with IL-2-protein and -gene therapy with special emphasis on head and neck cancer. Our own in vitro results with IL-2 gene therapy in conjunction with published data from other authors argue in favour of an in vivo approach for this therapeutic strategy that is currently in progress in our department.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 08/04/20 alle ore 08:23:21